Business

Charles River Laboratories to Present at Evercore Healthcare Conference

WILMINGTON, Mass., December 01, 2025--Charles River Laboratories to Present at Evercore Healthcare Conference

Charles River Laboratories International, Inc.December 1, 20251
Charles River Laboratories to Present at Evercore Healthcare Conference

About this update from Charles River Laboratories International, Inc.

WILMINGTON, Mass., December 01, 2025 --( BUSINESS WIRE )--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore 8 th Annual Healthcare Conference on Wednesday, December 3 rd , at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com . A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20251201475382/en/ Contacts Investor Relations Contact: Todd Spencer Corporate Vice President, Investor Relations 781.222.6455 [email protected]

View stock analysis, news, and events for Charles River Laboratories International, Inc.

Charles RiverBUSINESS WIRE

More from Charles River Laboratories International, Inc.

All Charles River Laboratories International, Inc. news →